
Fiorella Ilariucci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4444608/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36, 1870-1878.	7.2	47
2	MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e110-e121.	4.6	54
3	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. Ocular Immunology and Inflammation, 2021, , 1-9.	1.8	3
4	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a realâ€world setting. A GIMEMAâ€ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	2.8	12
5	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica, 2018, 103, 1209-1217.	3.5	30
6	Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. European Journal of Haematology, 2018, 101, 78-85.	2.2	5
7	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Oncotarget, 2018, 9, 23443-23450.	1.8	12
8	R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial. Blood, 2018, 132, 1687-1687.	1.4	0
9	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology.the. 2017. 4. e510-e523.	4.6	258
10	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. Journal of Clinical Oncology, 2016, 34, 1175-1181.	1.6	94
11	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. European Journal of Cancer, 2016, 60, 154-165.	2.8	22
12	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€ <scp>CLL</scp> 1â€ <scp>GISL</scp> study. European Journal of Haematology, 2016, 96, 36-45.	2.2	7
13	Reduced intensity <scp>VEPEMB</scp> regimen compared with standard <scp>ABVD</scp> in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (<scp>FIL</scp>). British Journal of Haematology, 2016, 172, 879-888.	2.5	29
14	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Leukemia and Lymphoma, 2016, 57, 1823-1830.	1.3	30
15	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. Blood. 2016. 128. 511-511.	1.4	13
16	Integrating Oncogeriatric Tools into the Management of Chronic Lymphocytic Leukemia: Current State of the Art and Challenges for the Future. Current Oncology Reports, 2015, 17, 31.	4.0	3
17	Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. Leukemia Research, 2015, 39, 840-845.	0.8	12
18	Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. British Journal of Haematology, 2015, 168, 455-459.	2.5	9

FIORELLA ILARIUCCI

#	Article	IF	CITATIONS
19	Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study. Blood, 2015, 126, 2946-2946.	1.4	1
20	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia. PLoS ONE, 2015, 10, e0118801.	2.5	15
21	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O LL1â€GISL study. American Journal of Hematology, 2014, 89, 743-750.	4.1	14
22	MATILDE chemotherapy regimen for primary CNS lymphoma. Neurology, 2014, 82, 1370-1373.	1.1	38
23	Highâ€throughput sequencing for the identification of <i><scp>NOTCH</scp>1</i> mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. British Journal of Haematology, 2014, 165, 629-639.	2.5	52
24	Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients. Blood, 2014, 124, 3074-3074.	1.4	1
25	Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study. Blood, 2014, 124, 3088-3088.	1.4	3
26	Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi. Blood, 2014, 124, 499-499.	1.4	1
27	A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report Journal of Clinical Oncology, 2014, 32, 8507-8507.	1.6	5
28	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3314-3314.	1.4	0
29	Total body computed tomography scan in the initial workâ€up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€CLL1â€GISL study. American Journal of Hematology, 2013, 88, 539-544.	4.1	10
30	Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (Râ€IE regimen) in patients with primary CNS lymphoma relapsed or refractory to highâ€dose methotrexateâ€based chemotherapy. Hematological Oncology, 2013, 31, 143-150.	1.7	66
31	Chromosome 2p gain in monoclonal B ell lymphocytosis and in early stage chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 24-31.	4.1	27
32	Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. Clinical Cancer Research, 2013, 19, 5890-5900.	7.0	60
33	Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09). Blood, 2013, 122, 3049-3049.	1.4	2
34	High-Throughput Sequencing For The Identification Of NOTCH1 mutations In Early Stage Chronic Lymphocytic Leukemia: Biological and Clinical Implications. Blood, 2013, 122, 1622-1622.	1.4	0
35	Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood, 2012, 120, 3858-3860.	1.4	58
36	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit― patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leukemia and Lymphoma, 2012, 53, 581-588.	1.3	74

FIORELLA ILARIUCCI

#	Article	IF	CITATIONS
37	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. British Journal of Haematology, 2012, 156, 346-353.	2.5	122
38	An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood, 2011, 118, 4079-4085.	1.4	28
39	Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia. PLoS ONE, 2011, 6, e24313.	2.5	36
40	Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VECF. Leukemia Research, 2010, 34, 312-321.	0.8	48
41	Enteropathy-associated T cell lymphoma of the jejunum associated with colonic lymphocytosis with aberrant phenotype. Journal of Clinical Pathology, 2010, 63, 850-852.	2.0	0
42	Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study. Blood, 2010, 116, 1384-1384.	1.4	0
43	Incidence Rate of Thromboembolic Events (TE) In a Prospectively Evaluated Population of Patients with Lymphoma Enrolled In First Line Treatment Clinical Trials: a Report From the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). Blood, 2010, 116, 4208-4208.	1.4	Ο
44	Anthracyclineâ€fludarabineâ€containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. Cancer, 2009, 115, 1906-1913.	4.1	6
45	Ocular involvement in nasal natural killer T-cell lymphoma. International Ophthalmology, 2009, 29, 275-279.	1.4	39
46	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. British Journal of Haematology, 2009, 144, 492-506.	2.5	106
47	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, The, 2009, 374, 1512-1520.	13.7	588
48	Temozolomide as salvage treatment in primary brain lymphomas. British Journal of Cancer, 2007, 96, 864-867.	6.4	135
49	R-CHOP vs R-MiniCEOP in Elderly Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) Prospectively Selected by a Multidimensional Evaluation Scale: Preliminary Results of a Randomized Study Performed by Intergruppo Italiano Linfomi (IIL) Blood, 2007, 110, 3429-3429.	1.4	1
50	Defibrotide Low-Dose Continuous Infusion from Day +1 Until Day +21 after Allogeneic Stem Cell Transplantation as Prophylaxis of Veno-Occlusive Disease (VOD) of the Liver. A Single Centre Experience Blood, 2007, 110, 4927-4927.	1.4	3
51	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience Blood, 2007, 110, 3089-3089.	1.4	Ο
52	MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology, 2006, 66, 1435-1438.	1.1	83
53	Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenström's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System. Journal of Clinical Oncology. 2005. 23. 4662-4668.	1.6	73
54	Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial. Journal of Clinical Oncology, 2004, 22, 424-431.	1.6	134

#	Article	IF	CITATIONS
55	Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Annals of Oncology, 2004, 15, 1215-1221.	1.2	111
56	Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the â€~cutaneous variant' ¹ . British Journal of Haematology, 2004, 127, 173-183.	2.5	535
57	Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas. Cancer, 2004, 101, 1601-1608.	4.1	40
58	Bleomycin, Epidoxorubicin, Cyclophosphamide, Vincristine and Prednisone (BACOP) in Patients with Follicular Non-Hodgkin's Lymphoma: Results of a Prospective, Multicenter Study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). Leukemia and Lymphoma, 2002, 43, 1795-1801.	1.3	6
59	Image-Aided Estimate of Tumor Burden in Hodgkin's Disease: Evidence of Its Primary Prognostic Importance. Journal of Clinical Oncology, 2001, 19, 1388-1394.	1.6	59